Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

      CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents’ flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation) (PRNewsfoto/CytoSorbents Corporation)

      News provided by

      Cytosorbents Corp

      May 13, 2026, 16:00 ET

      Share this article

      Share this article


      PRINCETON, N.J., May 13, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2026, recent business highlights, and provides a regulatory update. 

      First Quarter 2026 Financial Results

      • Revenue was $8.9 million, an increase of 2% over the prior year, from $8.7 million
      • Gross margin was 69% in the quarter compared to 71% in Q1 2025
      • Operating loss was $3.0 million, compared to $3.9 million in Q1 2025  
      • Net loss was $5.1 million or $0.08 per share, compared to a net loss of $1.5 million or $0.02 per share in Q1 2025.  The increase was due primarily to the non-cash impact of changes in foreign currency transactions year-over-year  
      • Adjusted net loss, which excludes the impact of non-cash changes in foreign currency transactions and non-cash stock compensation, was $3.4 million or $0.05 per share, compared to an adjusted net loss of $3.7 million or $0.06 per share in Q1 2025
      • Adjusted EBITDA loss, which also excludes the impact of non-cash changes in foreign currency transactions and non-cash stock compensation was $2.2 million compared to a loss of $2.7 million in Q1 2025
      • Total cash, cash equivalents, and restricted cash was approximately $6.4 million, compared to $7.8 million as of December 31, 2025  
      • Total cash burn in the quarter, excluding $0.3 million in restructuring-related payments, was approximately $1.1 million  

      "First quarter sales were $8.9 million, driven by 13% growth in our direct sales territories outside of Germany," stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents Corporation.  "Our Germany sales team also performed well, achieving sales slightly below last year, but with a smaller and more focused team – reflecting new leadership, sales execution, account targeting, productivity, and customer engagement.  Given the importance of the German market, we plan to selectively expand our commercial team to improve account coverage and drive growth opportunities in both critical care and cardiac surgery.

      Distributor sales were flat year-over-year, as progress across several territories was offset by delayed distributor orders of approximately $500,000 in parts of the Middle East and neighboring regions due to geopolitical and economic instability related to the U.S.-Iran war.  This unexpected disruption has slowed the anticipated growth of our recently established subsidiary in Dubai, UAE, although we expect conditions to improve as the conflict stabilizes.

      Gross margin declined marginally to 69% in the first quarter, primarily due to intentionally reduced production volumes aimed at lowering inventory levels and improving working capital.  

      In the fourth quarter of 2025, we implemented a strategic workforce and cost reduction initiative, reducing headcount by approximately 10% while lowering operating and production expenses.  The initial benefits of this program were reflected in lower expenses and improved operating margins in the first quarter.  Meanwhile, we have continued to make operational improvements and cost reductions and believe these actions will continue to drive improvements in the coming quarters to support our goal of achieving operating cash flow breakeven in the second half of this year."  

      DrugSorb-ATR® for Brilinta®

      "In August 2025, we received the FDA's decision on our appeal of the original DrugSorb-ATR application.  Importantly, the Agency identified no concerns regarding device safety but upheld the prior denial of the application and requested additional information to support the proposed indication for reducing the severity of perioperative bleeding in patients undergoing CABG surgery while on Brilinta® (ticagrelor, AstraZeneca).

      Following the appeal decision and based on feedback from FDA, we announced our intention to submit a new De Novo application incorporating additional supporting information, primarily based on real-world evidence and clinical outcomes generated through routine clinical use of the device.  As part of this process, we held a formal pre-submission meeting with the FDA in late January 2026 and have continued to engage with the Agency to clarify the requirements for the new De Novo submission, including whether all information would be required within the submission or as a post-marketing requirement. Based on these interactions, the FDA has requested additional mechanistic data to be included alongside the real-world evidence within the new De Novo submission.

      We are currently evaluating options to generate the additional mechanistic data on an expedited basis and expect to schedule an additional pre-submission meeting with the FDA, if needed, to discuss and align on the proposed approach.  Once alignment is achieved, we anticipate completing the required work and submitting a new De Novo application in late 2026 or early 2027.  Though delayed from our timeline, we now have clearer direction and are committed to obtaining the new information and filing a new De Novo submission as soon as possible.  Following submission, a regulatory decision would generally be expected within the FDA's targeted 150-day MDUFA review timeline, although the actual review period may be shorter or longer depending on the nature and extent of interactive review questions from the Agency.

      Meanwhile, the U.S. and Canadian pivotal STAR-T randomized, controlled trial results are now available in PDF form from the Journal of Thoracic and Cardiovascular Surgery (2026) - the leading peer-reviewed cardiothoracic surgery journal in the U.S., highlighting "Intraoperative use of DrugSorb-ATR is safe in patients operated within 2 days of ticagrelor discontinuation [with] significant reductions in severe bleeding events in the prespecified CABG subpopulation"

      DrugSorb-ATR for DOACs: Eliquis® and Xarelto®

      "We have previously discussed our intention, following anticipated FDA marketing approval of DrugSorb-ATR for Brilinta®, to pursue an expanded indication for the removal of direct oral anticoagulants (DOACs), such as Eliquis® (apixaban, Pfizer/BMS) and Xarelto® (rivaroxaban, Bayer/Janssen).  At the same time, we continue to observe increasing real-world adoption, clinical use, and published evidence supporting the use of our technology for DOAC removal in cardiac surgery, reinforcing the significant unmet medical need globally. 

      Within the next 30 days, we plan to submit a separate pre-submission request to the Agency to review the data currently available for the DOAC indication that include drug removal data from benchtop testing and data from real-world use and to determine what, if any, additional information may be required to support a parallel De Novo submission for DOAC removal. 

      Having this potential second shot on goal is aligned with our other FDA Breakthrough Device Designation for DrugSorb-ATR, to remove DOACs during cardiac surgery.  Globally, tens of millions of patients are on chronic or life-long DOAC therapy due to atrial fibrillation, deep vein thrombosis, pulmonary embolism, peripheral vascular disease, or post-surgical prophylaxis.  An estimated 5-10% of emergent cardiac surgery cases involve patients who are currently therapeutic on a DOAC and risk serious or life-threatening perioperative bleeding. 

      In 2025, Eliquis ranked #7 among the top-selling pharmaceuticals globally, generating approximately $14.4 billion in worldwide sales and accounting for a majority share of new oral anticoagulant prescriptions.  Xarelto generated approximately $5.1 billion in global sales. We estimate that the combined U.S. total addressable market for DrugSorb-ATR in cardiac surgery across Brilinta® and the DOACs is between $500 million and $1 billion annually."

      New Health Economic Analysis in Septic Shock

      "Finally, in our last earnings call update, we highlighted many key publications across critical care and cardiac surgery.  Recently, an important study entitled 'Impact of CytoSorb Hemoadsorption Therapy on Cost-Effectiveness and Length of Stay in Critical Care Patients: A Preliminary Study from a Swiss High-Volume Center", was published in the peer-reviewed journal Healthcare.  This study provides compelling real-world evidence for the cost-effectiveness of CytoSorb hemoadsorption in a comparative analysis of 246 ICU patients with septic shock.  Compared to patients treated with standard of care alone, those additionally treated with CytoSorb showed significant reductions in ICU and hospital length of stay, duration of mechanical ventilation among survivors, and nursing workload, while total hospital treatment costs were not significantly increased.  CytoSorb therapy showed a clear advantage in net case profitability (revenue minus costs), with significantly higher earnings per case compared to standard of care.  These results highlight the cost-effectiveness of CytoSorb therapy and the ability to achieve clinical, operational, and economic benefits in a resource-intensive critical care setting."

      Dr. Chan concluded, "While we continue to navigate what we believe to be temporary headwinds in the Middle East, we remain focused on executing on our key priorities including:  strengthening commercial performance, reducing operating expenses, and progressing toward our goal of achieving operating cash flow breakeven in the second half of this year.  At the same time, we are advancing the substantial long-term U.S. opportunity for DrugSorb-ATR.  We now have clearer regulatory direction from the FDA for our ticagrelor application and are actively evaluating a potential parallel path focused on DOACs that could significantly expand the U.S. market opportunity.  We believe the actions we are taking today are building a stronger, more resilient company and positioning us to deliver meaningful long-term value for patients, clinicians, and shareholders."  

      First Quarter 2026 Earnings Conference Call

      CytoSorbents' management will host a live conference call, presentation webcast, and a question-and-answer session with the following information:

      Date: Wednesday May 13, 2026
      Time: 4:30 PM ET
      Live webcast link: https://app.webinar.net/KbgRLmJk8ow

      It is recommended that participants join approximately 10 minutes prior to the start of the call.

      An archived recording of the conference call will be available under the Investor Relations section of the Company's website at https://ir.cytosorbents.com/ 

      About DrugSorb-ATR

      In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two U.S. Food and Drug Administration ("FDA") Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures.

      The Company continues to actively pursue regulatory approval of DrugSorb-ATR with the FDA and expects to pursue regulatory approval in Canada with better visibility from the FDA. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively.

      About Non-GAAP Financial Measures

      To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non-cash stock compensation expense, and gain or loss of foreign exchange translation. We also use the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Share which excludes non-cash stock compensation expense and gain or loss of foreign exchange translation from Net Loss and Net Loss Per Share, respectively. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by investors and the analyst community to help them analyze the performance of our business, the Company's cash available for operations, and the Company's ability to meet future capital expenditure and working capital requirements.  For a reconciliation of non-GAAP financial measures to the most comparable GAAP measure, see the reconciliation included in the financial tables.  All non-GAAP adjustments are presented pre-tax.

      About CytoSorbents Corporation (NASDAQ: CTSO)

      CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

      CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date.  CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber.  Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure.  CytoSorb is not yet approved or cleared in the United States.

      In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs.  It has received two FDA Breakthrough Device Designations:  one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery.  The Company is actively pursuing regulatory approval of DrugSorb-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA.  DrugSorb-ATR is not yet granted or approved in either the U.S. or Canada.

      The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, PuriFi®, HotSwap®, and others. For more information, please visit the Company's website at https://ir.cytosorbents.com/  or follow us on Facebook and X. 

      Forward-Looking Statements

      This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, the impact of geopolitical events including the recent war in Iran, our ability to successfully obtain U.S. FDA and Health Canada regulatory approval and marketing authorization, our ability to complete our strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve operating cash-flow break-even in the second half of 2026, our ability to appropriately finance the Company, including our ability to meet our financial obligations and comply with the covenants under our existing debt agreement, and the risks discussed in our Annual Report on Form 10-K, to be filed with the SEC by March 30, 2026, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

      Please Click to Follow Us on Facebook and X

      U.S. Company Contact:
      Peter J. Mariani, Chief Financial Officer
      305 College Road East
      Princeton, NJ 08540
      [email protected]

      CYTOSORBENTS CORPORATION

      CONDENSED CONSOLIDATED BALANCE SHEETS

      (in thousands, except share data)










      March 31, 


      December 31, 



      2026


      2025



      (unaudited)



      ASSETS







      Current Assets:







      Cash and cash equivalents


      $

      4,813


      $

      6,249

      Accounts receivable, net of allowances of $164 as of March 31, 2026 and
      December 31, 2025



      7,152



      7,550

      Inventories - net



      4,481



      5,281

      Prepaid expenses and other current assets



      1,311



      1,554

      Total current assets



      17,757



      20,634








      Property and equipment - net



      7,510



      7,823

      Restricted cash



      1,522



      1,522

      Right-of-use asset



      10,769



      10,924

      Patents - net



      2,952



      3,226

      Other assets



      52



      53

      Total assets


      $

      40,562


      $

      44,182








      LIABILITIES AND STOCKHOLDERS' EQUITY







      Current Liabilities:







      Accounts payable


      $

      3,132


      $

      2,869

      Accrued expenses and other current liabilities



      5,960



      6,299

      Lease liability – current portion



      565



      541

      Current maturities of long-term debt, net of debt discount



      6,646



      —

      Total current liabilities



      16,303



      9,709

      Lease liability, net of current portion



      11,752



      11,903

      Long-term debt, net of current portion and debt discount



      10,313



      16,667

      Total liabilities



      38,368



      38,279








      Commitments and Contingencies














      Stockholders' equity







      Preferred Stock, par value $0.001, 5,000,000 shares authorized; no shares
      issued and outstanding as of March 31, 2026 and December 31, 2025



      —



      —

      Common Stock, par value $0.001, 100,000,000 shares authorized as of
      March 31, 2026 and December 31, 2025; 62,733,305 and 62,804,305
      shares issued and outstanding as of March 31, 2026 and
      December 31, 2025 respectively



      63



      63

      Additional paid-in capital



      321,568



      321,024

      Accumulated other comprehensive loss



      (2,101)



      (2,977)

      Accumulated deficit



      (317,336)



      (312,207)

      Total stockholders' equity



      2,194



      5,903

      Total liabilities and stockholders' equity


      $

      40,562


      $

      44,182


      CYTOSORBENTS CORPORATION

      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)

      (in thousands, except share and per share data)










      Three Months Ended March 31, 



      2026


      2025

      Revenue, net


      $

      8,864


      $

      8,727

      Cost of goods sold



      2,734



      2,520

      Gross profit



      6,130



      6,207








      Operating expenses







      Research and development, net of grant income



      1,025



      1,663

      Selling, general and administrative



      8,149



      8,432

      Total operating expenses



      9,174



      10,095

      Loss from operations



      (3,044)



      (3,888)








      Other income (expense)







      Interest expense, net



      (857)



      (605)

      Gain (loss) on foreign currency transactions



      (1,228)



      3,014

      Total other income (expense), net



      (2,085)



      2,409








      Net loss


      $

      (5,129)


      $

      (1,479)








      Basic and diluted net loss per common share


      $

      (0.08)


      $

      (0.02)








      Weighted Average Shares of Common Stock Outstanding







      Basic and diluted



      62,738,827



      60,731,929








      Other comprehensive income (loss):







      Foreign currency translation adjustment, net of tax



      876



      (2,736)

      Comprehensive loss


      $

      (4,253)


      $

      (4,215)


      CYTOSORBENTS CORPORATION

      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)

      (in thousands, except share data)





























      Accumulated














      Additional


      Other









      Common Stock


      Paid-In


      Comprehensive


      Accumulated


      Stockholders'



      Shares


      Par Value


      Capital


      Income (Loss)


      Deficit


      Equity

      Balance at December 31, 2025


      62,804,305


      $

      63


      $

      321,024


      $

      (2,977)


      $

      (312,207)


      $

      5,903

      Stock-based compensation


      —



      —



      544



      —



      —



      544

      Reversal of excess RSU shares issued


      (71,000)



      —



      —



      —



      —



      —

      Foreign currency translation adjustment, net of tax


      —



      —



      —



      876



      —



      876

      Net loss


      —



      —



      —



      —



      (5,129)



      (5,129)

      Balance at March 31, 2026 


      62,733,305


      $

      63


      $

      321,568


      $

      (2,101)


      $

      (317,336)


      $

      2,194





























      Accumulated














      Additional


      Other









      Common Stock


      Paid-In


      Comprehensive


      Accumulated


      Stockholders'



      Shares


      Par Value


      Capital


      Income


      Deficit


      Equity

      Balance at December 31, 2024


      54,830,146


      $

      55


      $

      310,809


      $

      4,252


      $

      (304,009)


      $

      11,107

      Stock-based compensation


      32,321



      —



      818



      —



      —



      818

      Issuance of common stock from exercise of warrants


      1,417,208



      2



      1,437



      —



      —



      1,439

      Issuance of common stock and warrants from rights
      offerings, net of fees incurred


      6,249,791



      6



      5,386



      —



      —



      5,392

      Foreign currency translation adjustment, net of tax


      —



      —



      —



      (2,736)



      —



      (2,736)

      Net loss


      —



      —



      —



      —



      (1,479)



      (1,479)

      Balance at March 31, 2025


      62,529,466


      $

      63


      $

      318,450


      $

      1,516


      $

      (305,488)


      $

      14,541




















      CYTOSORBENTS CORPORATION

      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

      (in thousands)










      Three


      Three



      Months Ended


      Months Ended



      March 31, 


      March 31, 



      2026


      2025

      Cash flows from operating activities







      Net loss


      $

      (5,129)


      $

      (1,479)

      Adjustments to reconcile net loss to net cash used in operating activities:







      Amortization of debt discount



      291



      190

      Amortization of patents



      61



      63

      Depreciation



      289



      306

      Amortization of right-of-use asset



      26



      36

      Loss on abandoned patents



      274



      8

      Bad debt expense (recovery)



      (1)



      2

      Stock-based compensation



      544



      818

      Foreign currency transaction (gains) losses



      1,228



      (3,014)

      Changes in operating assets and liabilities







      Accounts receivable



      310



      (80)

      Inventories



      723



      (199)

      Prepaid expenses and other current assets



      129



      250

      Other assets



      1



      —

      Accounts payable and accrued expenses



      92



      (367)

      Net cash used in operating activities



      (1,162)



      (3,466)








      Cash flows from investing activities







      Purchases of property and equipment



      (11)



      (2)

      Disposals of property and equipment



      26



      —

      Payments for patent costs



      (61)



      (45)

      Net cash used in investing activities



      (46)



      (47)

      Cash flows from financing activities







      Cash for exercise of warrants, net



      —



      1,439

      Proceeds from rights offering, net



      —



      5,392

      Net cash provided by financing activities



      —



      6,831

      Effect of exchange rates on cash



      (228)



      28

      Net change in cash, cash equivalents, and restricted cash



      (1,436)



      3,346








      Cash, cash equivalents, and restricted cash at beginning of year



      7,771



      9,764

      Cash, cash equivalents, and restricted cash – end of period


      $

      6,335


      $

      13,110








      Supplemental disclosure of cash flow information







      Cash paid for interest


      $

      591


      $

      506








      Supplemental disclosure of non-cash financing activities







      Fair value of common stock warrants issued in connection with the rights offering



      —



      556

      Offering fees included in accounts payable


      $

      —


      $

      253


      RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES




      Three Months Ended



      March 31,



      2026


      2025



      (amounts, in thousands)

      Net income (loss)


      $

      (5,129)


      $

      (1,479)

      Depreciation and amortization expense


      $

      350


      $

      369

      Income tax expense (benefit)


      $

      -


      $

      -

      Interest expense (income)


      $

      857


      $

      605

      EBITDA – non-GAAP measure


      $

      (3,922)


      $

      (505)








      Non-cash stock-based compensation expense


      $

      544


      $

      818

      (Gain)/Loss on foreign currency transactions



      1,228



      (3,014)

      Adjusted EBITDA – non-GAAP measure


      $

      (2,150)


      $

      (2,701)








      Net income (loss)


      $

      (5,129)


      $

      (1,479)

      Non-cash stock-based compensation expense



      544



      818

      (Gain)/Loss on foreign currency transactions


      $

      1,228


      $

      (3,014)

      Adjusted net loss – non-GAAP measure


      $

      (3,357)


      $

      (3,675)

      Weighted average common shares outstanding







      Basic



      62,738,827



      60,731,929

      Diluted



      62,738,827



      60,731,929

      Basic net income (loss) per common share


      $

      (0.08)


      $

      (0.02)

      Diluted net income (loss) per common share


      $

      (0.08)


      $

      (0.02)








      Non-cash stock-based compensation expense - basic


      $

      0.01


      $

      0.01

      Non-cash stock-based compensation expense - diluted


      $

      0.01


      $

      0.01

      (Gain)/Loss on foreign currency transactions - basic


      $

      0.02


      $

      (0.05)

      (Gain)/Loss on foreign currency transactions - diluted


      $

      0.02


      $

      (0.05)

      Adjusted net income (loss) per common share – basic – non-
      GAAP measure


      $

      (0.05)


      $

      (0.06)

      Adjusted net income (loss) per common share – diluted –
      non-GAAP measure


      $

      (0.05)


      $

      (0.06)

      SOURCE Cytosorbents Corp

      Modal title

      Also from this source

      CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update

      CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update

      CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...

      CytoSorbents to Participate at the 2026 Jefferies Global Healthcare Conference in London

      CytoSorbents to Participate at the 2026 Jefferies Global Healthcare Conference in London

      CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Medical Equipment

      Medical Equipment

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.